TY - JOUR
T1 - Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
AU - Berenguer, Juan
AU - Ryan, Pablo
AU - Rodríguez-Baño, Jesús
AU - Jarrín, Inmaculada
AU - Carratalà, Jordi
AU - Pachón, Jerónimo
AU - Yllescas, María
AU - Arriba, José Ramón
AU - Aznar Muñoz, Esther
AU - Gil Divasson, Pedro
AU - González Muñiz, Patricia
AU - Muñoz Aguirre, Clara
AU - López, Juan Carlos
AU - Ramírez-Schacke, Margarita
AU - Gutiérrez, Isabel
AU - Tejerina, Francisco
AU - Aldámiz-Echevarría, Teresa
AU - Díez, Cristina
AU - Fanciulli, Chiara
AU - Pérez-Latorre, Leire
AU - Parras, Francisco
AU - Catalán, Pilar
AU - García-Leoni, María E.
AU - Pérez-Tamayo, Isabel
AU - Puente, Luis
AU - Cedeño, Jamil
AU - Díaz Menéndez, Marta
AU - de la Calle Prieto, Fernando
AU - Arsuaga Vicente, Marta
AU - Trigo Esteban, Elena
AU - Lago Núñez, Mª del Mar
AU - de Miguel Buckley, Rosa
AU - Cadiñaños Loidi, Julen
AU - Busca Arenzana, Carmen
AU - Mican, Alfredo
AU - Mora Rillo, Marta
AU - Ramos Ramos, Juan Carlos
AU - Knobel, Hernando
AU - Güerri-Fernández, Roberto
AU - Navarro Vilasaró, Marta
AU - Cervantes García, Manuel
AU - Gasch Blasi, Oriol
AU - Falgueras López, Luis
AU - López-Contreras González, Joaquín
AU - Pomar Solchaga, Virginia
AU - Rabella García, Nuria
AU - Benito Hernández, Natividad
AU - Bonfill Cosp, Xavier
AU - Puig Campmany, Mireia
AU - Mancebo Cortés, Jordi
N1 - Funding Information:
This work was supported by Fundación SEIMC/GeSIDA . JB, JR-B, IJ, JC, JP and JRA received funding for research from Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III , Subdirección General de Redes y Centros de Investigación Cooperativa , Ministerio de Ciencia, Innovación y Universidades , cofinanced by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligent Growth 2014–2020, Spanish AIDS Research Network (RIS) (RD16/0025/0017 (JB), RD16/0025/0018 (JRA), RD16CIII/0002/0006 (IJ)) and Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016/0001 (JRB), RD16/0016/0005 (JC) and RD16/0016/0009 (JP).
Funding Information:
JB reports grants and personal fees from AbbVie, grants and personal fees from Gilead, grants and personal fees from MSD, grants and personal fees from ViiV Healthcare and personal fees from Janssen, outside the submitted work. PR reports personal fees from AbbVie, grants and personal fees from Gilead, personal fees from Janssen, grants from MSD and personal fees from ViiV Healthcare, outside the submitted work. IJ reports personal fees from Gilead and ViiV Healthcare, outside the submitted work. JRA reports grants and personal fees from Alexa, grants and personal fees from Gilead, grants and personal fees from MSD, grants and personal fees from Janssen, grants and personal fees from Serono, grants and personal fees from Teva and grants and personal fees from ViiV Healthcare, outside the submitted work. The other authors report no conflicts of interest relevant to this article.
Publisher Copyright:
© 2020 European Society of Clinical Microbiology and Infectious Diseases
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - Objectives: To analyse the characteristics and predictors of death in hospitalized patients with coronavirus disease 2019 (COVID-19) in Spain. Methods: A retrospective observational study was performed of the first consecutive patients hospitalized with COVID-19 confirmed by real-time PCR assay in 127 Spanish centres until 17 March 2020. The follow-up censoring date was 17 April 2020. We collected demographic, clinical, laboratory, treatment and complications data. The primary endpoint was all-cause mortality. Univariable and multivariable Cox regression analyses were performed to identify factors associated with death. Results: Of the 4035 patients, male subjects accounted for 2433 (61.0%) of 3987, the median age was 70 years and 2539 (73.8%) of 3439 had one or more comorbidity. The most common symptoms were a history of fever, cough, malaise and dyspnoea. During hospitalization, 1255 (31.5%) of 3979 patients developed acute respiratory distress syndrome, 736 (18.5%) of 3988 were admitted to intensive care units and 619 (15.5%) of 3992 underwent mechanical ventilation. Virus- or host-targeted medications included lopinavir/ritonavir (2820/4005, 70.4%), hydroxychloroquine (2618/3995, 65.5%), interferon beta (1153/3950, 29.2%), corticosteroids (1109/3965, 28.0%) and tocilizumab (373/3951, 9.4%). Overall, 1131 (28%) of 4035 patients died. Mortality increased with age (85.6% occurring in older than 65 years). Seventeen factors were independently associated with an increased hazard of death, the strongest among them including advanced age, liver cirrhosis, low age-adjusted oxygen saturation, higher concentrations of C-reactive protein and lower estimated glomerular filtration rate. Conclusions: Our findings provide comprehensive information about characteristics and complications of severe COVID-19, and may help clinicians identify patients at a higher risk of death.
AB - Objectives: To analyse the characteristics and predictors of death in hospitalized patients with coronavirus disease 2019 (COVID-19) in Spain. Methods: A retrospective observational study was performed of the first consecutive patients hospitalized with COVID-19 confirmed by real-time PCR assay in 127 Spanish centres until 17 March 2020. The follow-up censoring date was 17 April 2020. We collected demographic, clinical, laboratory, treatment and complications data. The primary endpoint was all-cause mortality. Univariable and multivariable Cox regression analyses were performed to identify factors associated with death. Results: Of the 4035 patients, male subjects accounted for 2433 (61.0%) of 3987, the median age was 70 years and 2539 (73.8%) of 3439 had one or more comorbidity. The most common symptoms were a history of fever, cough, malaise and dyspnoea. During hospitalization, 1255 (31.5%) of 3979 patients developed acute respiratory distress syndrome, 736 (18.5%) of 3988 were admitted to intensive care units and 619 (15.5%) of 3992 underwent mechanical ventilation. Virus- or host-targeted medications included lopinavir/ritonavir (2820/4005, 70.4%), hydroxychloroquine (2618/3995, 65.5%), interferon beta (1153/3950, 29.2%), corticosteroids (1109/3965, 28.0%) and tocilizumab (373/3951, 9.4%). Overall, 1131 (28%) of 4035 patients died. Mortality increased with age (85.6% occurring in older than 65 years). Seventeen factors were independently associated with an increased hazard of death, the strongest among them including advanced age, liver cirrhosis, low age-adjusted oxygen saturation, higher concentrations of C-reactive protein and lower estimated glomerular filtration rate. Conclusions: Our findings provide comprehensive information about characteristics and complications of severe COVID-19, and may help clinicians identify patients at a higher risk of death.
KW - Coronavirus
KW - COVID-19
KW - Pneumonia
KW - Respiratory distress syndrome
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85092047820&partnerID=8YFLogxK
U2 - 10.1016/j.cmi.2020.07.024
DO - 10.1016/j.cmi.2020.07.024
M3 - Article
C2 - 32758659
AN - SCOPUS:85092047820
SN - 1198-743X
VL - 26
SP - 1525
EP - 1536
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 11
ER -